Trials / Recruiting
RecruitingNCT04564781
Predicting BCG Response
A Novel Multiplex Immunoassay for Predicting Intravesical BCG Response in Patients With Intermediate or High-risk Non-muscle Invasive Bladder Cancer
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 400 (estimated)
- Sponsor
- Cedars-Sinai Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
To date, there are no diagnostics capable of predicting treatment response to intravesical BCG. Because of this severe limitation, nearly 50% of patients treated with BCG fail therapy and will a) require additional intravesical therapy or b) require cystectomy. A urine-based diagnostic that possesses the potential to accurately identify patients who will respond favorably to intravesical BCG is desperately needed.
Conditions
Timeline
- Start date
- 2020-09-18
- Primary completion
- 2030-02-01
- Completion
- 2030-02-01
- First posted
- 2020-09-25
- Last updated
- 2026-02-04
Locations
5 sites across 2 countries: United States, Japan
Source: ClinicalTrials.gov record NCT04564781. Inclusion in this directory is not an endorsement.